MARKET

TKVA

TKVA

Salspera, Inc.
NASDAQ
--
0.00
0.00%
Closed
OPEN
--
PREV CLOSE
--
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
--
52 WEEK LOW
--
MARKET CAP
--
P/E (TTM)
--
1D
5D
1M
3M
1Y
5Y
1D
U.S. IPO Weekly Recap: REIT Carve-Out Sees Solid Demand While Drone Micro-Cap Soars 500%+
Seeking Alpha · 03/21 06:03
U.S. IPO Weekly Recap: Asthma-Focused Generate Biomedicines Closes Out February IPO Market
Seeking Alpha · 02/28 02:25
Salspera Seeks $85 Million IPO On Thin Capitalization And Long Time Horizon
Seeking Alpha · 02/26 10:30
About TKVA
Salspera, Inc. focuses on the development and commercialization of a new class of Immunotherapeutics for the treatment of solid tumors. This new class of drugs, sometimes referred to as live biopharmaceuticals, are genetically modified biological agents which have the capability of expressing select antitumoral agents within the tumor’s microenvironment. The Company has an advanced pipeline of drug candidates in various stages of development for the treatment of pancreatic cancer, osteosarcoma cancers, gastrointestinal cancers and other early-stage programs/non-oncological diseases. Its lead program, Saltikva, is an attenuated strain of Salmonella Typhimurium that is non-toxic and orally administered. Saltikva is a bacteria-based, targeted cancer immunotherapy, orally administered using attenuated salmonella typhimurium. It is engineered to deliver human Interleukin-2 (IL-2) directly into tumors.

Webull offers Salspera, Inc stock information, including NASDAQ: TKVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TKVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TKVA stock methods without spending real money on the virtual paper trading platform.